St. Jude Care & Treatment

Menu

Close

Recruiting

RESESTX: Reduce Transfusion Infection

About this study

Blood transfusions are given to patients who need blood products when their bodies cannot make enough of the blood cells they need. Several types of cells are found in blood. One of the most important is the red blood cell (RBC). It carries oxygen from the lungs to the body’s organs and tissues. Patients with anemia from sickle cell disease or other blood disorders often need RBC transfusions.

Before a transfusion, the blood is tested for common infections. Infection from a blood transfusion is rare, but the risk can be greater in certain areas of the world. For example, some places have a greater risk for infections such as the Zika virus. This virus is passed to people by infected mosquitoes.

The INTERCEPT® Blood System for Red Blood Cells can inactivate many types of germs that cause infections from transfusions. RBCs are treated with this device to reduce transfusion infection risk and improve blood safety before the cells are given to a patient.

In this phase 3 study, we will test the use of the INTERCEPT system in patients with anemia from sickle cell disease (HbSS, HbSC or HbSB0 thalassemia). These patients often need regular RBC transfusions. We want to know if the patients react to the RBDs treated with the INTERCEPT system the same as regular RBCs.

Patients will receive blood transfusions with RBCs that were either treated with the INTERCEPT system or were not. Patients will be enrolled in the study for about 10 months. They will receive the same number of transfusions they usually need. Enrolled patients will provide information about their health and blood samples.

Eligibility overview

  • Ages 4 and up
  • Sickle cell disease (HbSS, HbSC or HbSB0 thalassemia)
  • Require regular red blood cell transfusions
  • Not pregnant

Request a referralLearn about clinical research

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.

Overview

Full title:

A Randomized, Double-Blind, Controlled, Parallel Group Study with the INTERCEPT® Blood System for Red Blood Cells in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections (RedeS Study) and Treatment Use Open-Label Extension Study

Study goal:

To study the safety and use of red blood cells prepared with the INTERCEPT® Blood System for Red Blood Cells as compared with red blood cells that are not prepared with this system.  

Diagnosis:

Sickle Cell Disease, Sickle Cell Anemia, Blood Disorders

Age:

Ages 4 and up

Clinical trials categories:

Sickle Cell Anemia Blood Disorders Infectious Diseases Sickle Cell Disease

For physicians and researchers

Patients accepted to St. Jude must be referred by a physician or other qualified medical professional. Learn how St. Jude can partner with you to care for your patient.

 

Learn more